| miRagen Receives Validation of its miRNA Platform with Servier Collaboration |
Abstract
|
|
Heather Cartwright |
|
| MedImmune to Advance AgonOx’s OX40 Cancer Agonists in Global Collaboration |
Abstract
|
|
Heather Cartwright |
|
| Celgene Invests US$45 M in Quanticel in Cancer Collaboration with Buyout Option |
Abstract
|
|
Heather Cartwright |
|
| Ablynx and Merck Serono Form Third Nanobody® Collaboration |
Abstract
|
|
Heather Cartwright |
|
| Biogen Idec and Portola Pharmaceuticals Collaborate on Oral Syk Inhibitors for Autoimmune Diseases |
Abstract
|
|
Heather Cartwright |
|
| Aslan Pharmaceuticals Licenses Regional Rights to BMS’ Early-Stage Cancer Drug |
Abstract
|
|
Heather Cartwright |
|
| Lundbeck and Otsuka Forge US$1.8 B Global CNS Alliance |
Abstract
|
|
Heather Cartwright |
|
| Roche Expands its HCV Pipeline with Anadys Pharmaceuticals Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Cubist Looks to Opioid Receptor Antagonists with Potential US$415 M Adolor Takeover |
Abstract
|
|
Heather Cartwright |
|
| ViroPharma to Broaden its Orphan Drug Portfolio with DuoCort Pharma Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Repligen Agrees to Buy Novozymes Biopharma Sweden to Increase its Revenue Potential |
Abstract
|
|
Heather Cartwright |
|
| Salix Expands its Product Portfolio with US$300 M Oceana Therapeutics Buyout |
Abstract
|
|
Heather Cartwright |
|
